­ Hemostemix Inc. announced the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board. Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and Health Sciences at McGill University, the Director of the McGill Regenerative Medicine Network, and a Professor in the Department of Pharmacology and Therapeutics. In 2020, he was awarded the Canadian Pacific Chair in Biotechnology, 2020 ­ 2025. He completed his PhD in Medical Genetics at the University of Toronto. Dr. Hébert's research is focused on a better understanding of the wiring of G protein-coupled receptor (GPCR) and G protein signalling architectures to inform drug discovery for a number of important diseases including heart disease. While his work has generated potentially unique therapeutic targets in heart disease, with a focus on fibrosis and hypertrophy in different types of cardiomyopathy, his work may also impact cancer and a rare neurodevelopmental disease affected by somatic and germline mutations in G subunits (GNB1), which he is poised to study after constructing a significant mutational toolkit. In addition, Dr. Hébert's work now orients
toward a molecular understanding of dilated cardiomyopathy using primary cardiomyocytes, cardiac fibroblasts, and iPSC-derived cells from patients.